| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 西藏奇正藏药股份有限公司（简称奇正藏药）是国内藏药龙头企业,主要从事新型藏药的研发、生产和销售，现拥有GMP药厂、GSP营销公司等全资及控股子公司21家，员工2974人，25个独家品种和141个药品批准文号，产品涵盖骨骼肌肉系统、神经系统、消化系统、心脑血管、呼吸系统、泌尿系统、妇科、皮肤科、儿科等领域。其中以奇正消痛贴膏为代表的外用止痛药物系列已在国内畅销多年并行销海外，临床有效率高，销售额在中国外用止痛药物市场连续多年名列前茅。 奇正藏药1995年落户西藏林芝,以千年藏药现代传承为己任，通过文化传承和科技创新带动传统藏药产业创新升级。公司被认定为首批国家创新型企业、国家级高新技术企业、国家技术创新示范企业、国家火炬计划重点高新技术企业、国家级企业技术中心，拥有两个国家地方联合实验室，先后实施国家“十一五”科技支撑计划重点项目、承担国家“十二五”、“十三五”科技重大专项。 公司在二十多年的经营实践中，秉持“向善利他正道正业”的核心价值观，自发、自觉地践行企业社会责任，始终保持动机与发心的善念，志愿维护自然和社会生态的共生共荣，形成了独具特色的可持续发展体系。截至2022年底，公司累计投入1.501亿元用于藏区和西部的医疗、教育、乡村振兴，及“新冠”疫情防控捐赠等社会公益事业。 公司自上市以来，始终专注主业，保持业绩的稳步持续增长。2022年，公司全年实现营业收入20.45亿，同比增长15.49%；归属于上市公司股东的扣除非经常性损益的净利润4.4亿元，同比增长27.57%。 | ||||||||||||||||||||||||
| Main Business | 藏药的研发、生产和销售，包括外用止痛药物、口服药等 | ||||||||||||||||||||||||
| Legal Representative | 刘凯列 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 冯平 | ||||||||||||||||||||||||
| Solicitors | 北京市天银律师事务所 | ||||||||||||||||||||||||
| Auditors | 利安达会计师事务所有限责任公司 | ||||||||||||||||||||||||
| Tel No | 010-84766012 | ||||||||||||||||||||||||
| Fax No | 010-84766081 | ||||||||||||||||||||||||
| Website | www.cheezheng.com.cn | ||||||||||||||||||||||||
| qzzy@qzh.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 28/08/2009 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.097 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.480 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 6.764 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 11.500B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |